Helaina, the company using precision fermentation to recreate immune-equivalent proteins previously only available in breast milk, announced today it has raised $20 million in Series A funding. The round was co-led by Spark Capital and Siam Capital, with additional investment from Primary Venture Partners, Plum Alley Investments, Tom Williams, Hannah Bronfman, Gabrielle Union, Matt Rutler and Barrel Ventures, among other strategic partners. The new infusion of funds, which brings total capital raised to $24.6 million, will be used to begin its manufacturing and commercialization process and execute its go-to-market strategy, as well as further the company’s talent acquisition efforts.
Helaina raises $20 million in Series A to scale production of its human milk proteins using precision fermentation Co-Led by Spark Capital and Siam Capital
ByGrégory Maubon
Nov 25, 2021
By Grégory Maubon
Leading Innovation ++ on the Field ++ with a Purpose => I used AI in cultivated meat industry to optimize bioreactor design and to dramatically improve the efficiency and quality of production. I developed high quality 3D imagery process in a biotechnological startup to disrupt the drug discovery methods.